
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
PMVP is up 8.40% today. Volume is 258.8K vs a 30-day average of 735.7K (0.35x).
PMV Pharmaceuticals, Inc. is scheduled to report earnings Thu, Nov 5, 2026. Analysts expect EPS of $-0.35. Stocks often move sharply on earnings day.

PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.